Comprehensive genotyping in dyslipidemia: Mendelian dyslipidemias caused by rare variants and Mendelian randomization studies using common variants

Journal of Human Genetics

Volumn 62, Issue 4, 2017, Pages 453-458

  Tada, Hayato ^a   Kawashiri, Masa Aki ^a   Yamagishi, Masakazu ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PROPROTEIN CONVERTASE 9; LIPID;

CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DISEASE COURSE; DYSLIPIDEMIA; ETHNICITY; FAMILIAL HYPERCHOLESTEROLEMIA; GENE AMPLIFICATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LOSS OF FUNCTION MUTATION; MENDELIAN RANDOMIZATION ANALYSIS; NEXT GENERATION SEQUENCING; POLYMERASE CHAIN REACTION; REVIEW; RNA SEQUENCE; SANGER SEQUENCING; SINGLE NUCLEOTIDE POLYMORPHISM; WHOLE EXOME SEQUENCING; BLOOD; GENETIC VARIATION; GENETICS; HIGH THROUGHPUT SEQUENCING; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR;

CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DYSLIPIDEMIAS; GENETIC VARIATION; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LIPIDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 85016302067     PISSN: 14345161     EISSN: 1435232X     Source Type: Journal    
DOI: 10.1038/jhg.2016.159     Document Type: Review

References (53)

1. Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., et al. Executive summary: heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 127, 143-152 (2013).
2. Arsenault, B. J., Boekholdt, S. M., Kastelein, J. J. Lipid parameters for measuring risk of cardiovascular disease. Nat. Rev. Cardiol. 8, 197-206 (2011).
3. Emerging Risk Factors Collaboration, Di Angelantonio, E., Sarwar, N., Perry, P., Kaptoge, S., Ray, K. K., et al. Major lipids, apolipoproteins, risk of vascular disease. JAMA 302, 1993-2000 (2009).
4. Weiss, L. A., Pan, L., Abney, M., Ober, C. The sex-specific genetic architecture of quantitative traits in humans. Nat. Genet. 38, 218-222 (2006).
5. Kathiresan, S., Srivastava, D. Genetics of human cardiovascular disease. Cell 148, 1242-1257 (2012).
6. Watson, J. D., Crick, F. H. Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature 171, 737-738 (1953).
7. Maxam, A. M., Gilbert, W. A new method for sequencing DNA. Proc. Natl Acad. Sci. USA 74, 560-564 (1977).
8. Sanger, F., Nicklen, S., Coulson, A. R. DNA sequencing with chain-terminating inhibitors. Proc. Natl Acad. Sci. USA 74, 5463-5467 (1977).
9. Dewey, F. E., Pan, S., Wheeler, M. T., Quake, S. R., Ashley, E. A. DNA sequencing: clinical applications of new DNA sequencing technologies. Circulation 125, 931-944 (2012).
10. Stitziel, N. O., Peloso, G. M., Abifadel, M., Cefalu, A. B., Fouchier, S., Motazacker, M. M., et al. Exome sequencing in suspected monogenic dyslipidemias. Circ. Cardiovasc. Genet. 8, 343-350 (2015).
11. Tada, H., Kawashiri, M. A., Nohara, A., Saito, R., Tanaka, Y., Nomura, A., et al. Whole exome sequencing combined with integrated variant annotation prediction identifies asymptomatic Tangier disease with compound heterozygous mutations in ABCA1 gene. Atherosclerosis 240, 324-329 (2015).
12. Tada, H., Kawashiri, M. A., Yamagishi, M., Hayashi, K. Whole exome sequencing in monogenic dyslipidemias. J. Atheroscler. Thromb. 22, 881-885 (2015).
13. Butkiewicz, M., Bush, W. S. In silico functional annotation of genomic variation. Curr. Protoc. Hum. Genet. 88, 15. 1-6. 15. 17 (2016).
14. Exome Aggregation Consortium (ExAC), Cambridge, MA. Available at: http://exac. broadinstitute. org (last accessed November 2016).
15. Ference, B. A. Mendelian randomization studies: using naturally randomized genetic data to fill evidence gaps. Curr. Opin. Lipidol. 26, 566-571 (2015).
16. Kathiresan, S., Willer, C. J., Peloso, G. M., Demissie, S., Musunuru, K., Schadt, E. E, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat. Genet. 41, 56-65 (2009).
17. Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466, 707-713 (2010).
18. Global Lipids Genetics Consortium, Willer, C. J., Schmidt, E. M., Sengupta, S., Peloso, G. M., Gustafsson, S., et al. Discovery and refinement of loci associated with lipid levels. Nat. Genet. 45, 1274-1283 (2013).
19. Schunkert, H., König, I. R., Kathiresan, S., Reilly, M. P., Assimes, T. L., Holm, H., et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat. Genet. 43, 333-338 (2011).
20. Ference, B. A., Yoo, W., Alesh, I., Mirowska, K. K., Mewada, A., Kahn, J., et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J. Am. Coll. Cardiol. 60, 2631-2639 (2012).
21. CARDIoGRAMplusC4D Consortium, Deloukas, P., Kanoni, S., Willenborg, C., Farrall, M., Assimes, T. L., et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat. Genet. 45, 25-33 (2013).
22. Genest, J. J. Jr, Martin-Munley, S. S., McNamara, J. R., Ordovas, J. M., Jenner, J., Myers, R. H., et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 85, 2025-2033 (1992).
23. Kannel, W. B. High density lipoproteins: epidemiologic profile and risks of coronary artery disease. Am. J. Cardiol. 52, 9B-12B (1983).
24. Okamura, T., Hayakawa, T., Kadowaki, T., Kita, Y., Okayama, A., Ueshima, H., et al. The inverse relationship between serum high-density lipoprotein cholesterol level and all-cause mortality in a 9. 6-year follow-up study in the Japanese general population. Atherosclerosis 184, 143-150 (2006).
25. Inazu, A., Brown, M. L., Hesler, C. B., Agellon, L. B., Koizumi, J., Takata, K., et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N. Engl. J. Med. 323, 1234-1238 (1990).
26. Nissen, S. E., Tardif, J. C., Nicholls, S. J., Revkin, J. H., Shear, C. L., Duggan, W. T., et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. 356, 1304-1316 (2007).
27. Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367, 2089-2099 (2012).
28. AIM-HIGH Investigators, Boden, W. E., Probstfield, J. L., Anderson, T., Chaitman, B. R., Desvignes-Nickens, P., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365, 2255-2267 (2011).
29. Haase, C. L., Tybjærg-Hansen, A., Grande, P., Frikke-Schmidt, R. Genetically elevated apolipoprotein A-I, high-density lipoprotein cholesterol levels, risk of ischemic heart disease. J. Clin. Endocrinol. Metab. 95, E500-E510 (2010).
30. Voight, B. F., Peloso, G. M., Orho-Melander, M., Frikke-Schmidt, R., Barbalic, M., Jensen, M. K., et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380, 572-580 (2012).
31. Austin, M. A., Rodriguez, B. L., McKnight, B., McNeely, M. J., Edwards, K. L., Curb, J. D., et al. Low-density lipoprotein particle size, triglycerides, high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men. Am. J. Cardiol. 86, 412-416 (2000).
32. Sharrett, A. R., Ballantyne, C. M., Coady, S. A., Heiss, G., Sorlie, P. D., Catellier, D., et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 104, 1108-1113 (2001).
33. Do, R., Willer, C. J., Schmidt, E. M., Sengupta, S., Gao, C., Peloso, G. M., et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat. Genet. 45, 1345-1352 (2013).
34. Tarugi, P., Averna, M., Di Leo, E., Cefalù, A. B., Noto, D., Magnolo, L., et al. Molecular diagnosis of hypobetalipoproteinemia: an ENID review. Atherosclerosis 195, e19-e27 (2007).
35. Kastelein, J. J., Wedel, M. K., Baker, B. F., Su, J., Bradley, J. D., Rosie, Z. Y., et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by shortterm administration of an antisense inhibitor of apolipoprotein B. Circulation 114, 1729-1735 (2006).
36. Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M. J., Cromwell, W. C., et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375, 998-1006 (2010).
37. Stein, E. A., Dufour, R., Gagne, C., Gaudet, D., East, C., Donovan, J. M., et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 126, 2283-2292 (2012).
38. Santos, R. D., Duell, P. B., East, C., Guyton, J. R., Moriarty, P. M., Chin, W., et al. Longterm efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur. Heart J. 36, 566-575 (2015).
39. Katsuda, S., Kawashiri, M. A., Inazu, A., Tada, H., Tsuchida, M., Kaneko, Y., et al. Apolipoprotein B gene mutations and fatty liver in Japanese hypobetalipoproteinemia. Clin. Chim. Acta 399, 64-68 (2009).
40. Kawashiri, M. A., Tada, H., Hashimoto, M., Taniyama, M., Nakano, T., Nakajima, K., et al. Extreme contrast of postprandial remnant-like particles formed in abetalipoproteinemia and homozygous familial hypobetalipoproteinemia. JIMD Rep. 22, 85-94 (2015).
41. Cuchel, M., Bloedon, L. T., Szapary, P. O., Kolansky, D. M., Wolfe, M. L., Sarkis, A., et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N. Engl. J. Med. 356, 148-156 (2007).
42. Cuchel, M., Meagher, E. A., du Toit Theron, H., Blom, D. J., Marais, A. D., Hegele, R. A., et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 381, 40-46 (2013).
43. Yang, X. P., Inazu, A., Yagi, K., Kajinami, K., Koizumi, J., Mabuchi, H. Abetalipoproteinemia caused by maternal isodisomy of chromosome 4q containing an intron 9 splice acceptor mutation in the microsomal triglyceride transfer protein gene. Arterioscler. Thromb. Vasc. Biol. 19, 1950-1955 (1999).
44. Abifadel, M., Varret, M., Rabès, J. P., Allard, D., Ouguerram, K., Devillers, M., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34, 154-156 (2003).
45. Cohen, Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., Hobbs, H. H. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37, 161-165 (2005)
46. Cohen, J. C., Boerwinkle, E., Mosley, T. H. Jr & Hobbs, H. H. Sequence variations in PCSK9, low LDL, protection against coronary heart disease. N. Engl. J. Med. 354, 1264-1272 (2006).
47. Shimada, Y. J., Cannon, C. P. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, the future. Eur. Heart. J. 36, 2415-2424 (2015).
48. Zhao, Z., Tuakli-Wosornu, Y., Lagace, T. A., Kinch, L., Grishin, N. V., Horton, J. D., et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am. J. Hum. Genet. 79, 514-523 (2006).
49. Do, R., Stitziel, N. O., Won, H. H., Jørgensen, A. B., Duga, S., Merlini, P. A., et al. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature 518, 102-106 (2015).
50. Helgadottir, A., Gretarsdottir, S., Thorleifsson, G., Hjartarson, E., Sigurdsson, A., Magnusdottir, A., et al. Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease. Nat. Genet. 48, 634-639 (2016).
51. Surakka, I., Horikoshi, M., Mägi, R., Sarin, A. P., Mahajan, A., Lagou, V., et al. The impact of low-frequency and rare variants on lipid levels. Nat. Genet. 47, 589-897 (2015).
52. Peloso, G. M., Auer, P. L., Bis, J. C., Voorman, A., Morrison, A. C., Stitziel, N. O., et al. Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56, 000 whites and blacks. Am. J. Hum. Genet. 94, 223-232 (2014).
53. Tang, C. S., Zhang, H., Cheung, C. Y., Xu, M., Ho, J. C., Zhou, W., et al. Exome-wide association analysis reveals novel coding sequence variants associated with lipid traits in Chinese. Nat. Commun. 6, 10206 (2015).